Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , makes no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . ☑ CSPC CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集團 有限公司 ( Incorporated in Hong Kong with limited liability ) ( Stock Code : 1093 ) 2026 INTERIM RESULTS The Board of Directors ( the “ Board ” ) of CSPC Pharmaceutical Group Limited ( the “ Company ” ) is pleased to announce the unaudited consolidated results of the Company and its subsidiaries ( the " Group " ) for the six months ended 30 June 2026 . FINANCIAL HIGHLIGHTS ( in RMB'000 , unless otherwise stated ) Revenue by business units : Six months ended 30 June 2026 2025 Change Finished drugs 16,060,711 10,247,652 + 56.7 % Bulk products 1,660,385 2,074,708 -20.0 % Functional food and others 873,398 951,056 -8.2 % Total revenue 18,594,494 13,273,416 + 40.1 % Profit attributable to shareholders of the Company Reported 6,094,212 2,547,851 + 139.2 % Underlying ( note ) 6,164,279 2,319,521 + 165.8 % Earnings per share ( RMB cents ) Based on reported profit attributable to shareholders of the Company Basic 53.45 22.29 + 139.8 % ― Diluted 53.36 22.29 + 139.4 % Interim dividend per share ( HK cents ) 18.00 14.00 + 28.6 % Note : Underlying profit attributable to shareholders of the Company , a non - HKFRS Accounting Standards measure , represents the profit attributable to shareholders of the Company before taking into account fair value changes on financial assets measured at fair value through profit or loss ( " FVTPL " ) and employee share - based compensation expenses . A reconciliation between reported and underlying profit is provided on page 30 of this announcement . − 1 − -